首页 › 卵巢癌 › 俄克拉荷马州 › Oklahoma City
Oklahoma City OK 卵巢癌临床试验
28项针对 卵巢癌的研究正在 Oklahoma City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中欢迎健康志愿者
- University of Oklahoma Health Sciences Center, Oklahoma City
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
招募中1/2 期
- OU Health, Stephenson Cancer Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- University of Oklahoma, Oklahoma City
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
招募中2 期
- OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
Study of AVZO-021 in Patients With Advanced Solid Tumors
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
招募中1/2 期
- Stephenson Cancer Center, Oklahoma City
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
招募中3 期
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- University of Oklahoma, Oklahoma City
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
招募中1/2 期
- OU Health Stephenson Cancer Center, Oklahoma City
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
招募中3 期
- Oklahoma University Health Stephenson Cancer Center, Oklahoma City
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
招募中1 期
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Oklahoma City
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
招募中
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
A Study of DM002 in Patients With Advanced Solid Tumors
招募中1/2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
招募中3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- University of Oklahoma - Health Sciences Center, Oklahoma City
Clinical Pre-screening Protocol for Ovarian Cancer
招募中观察性研究
- OU Health Stephenson Cancer Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
招募中1/2 期
- Stephenson Cancer Center, Oklahoma City
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
招募中2/3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
招募中2 期
- University of Oklahoma, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
招募中欢迎健康志愿者
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
招募中1 期
- Stephenson Cancer Center, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
招募中1 期
- Dren Investigational Site, Oklahoma City
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
招募中2 期
- Stephenson Cancer Center at the University of Oklahoma, Oklahoma City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
招募中1 期
- Exelixis Clinical Site #13, Oklahoma City
其他城市的 卵巢癌试验
- Houston, TX89 项研究
- New York City, NY69 项研究
- Boston, MA61 项研究
- Los Angeles, CA50 项研究
- Nashville, TN49 项研究
- Arlington, VA46 项研究
- Philadelphia, PA44 项研究
- Columbus, OH39 项研究
- St. Louis, MO38 项研究
- Chicago, IL36 项研究
- San Antonio, TX31 项研究
- Cleveland, OH30 项研究
Oklahoma City的其他研究
- 非小细胞肺癌28 项研究
- 子宫内膜癌25 项研究
- 结直肠癌22 项研究
- 前列腺癌21 项研究
- 肺癌19 项研究
- 乳腺癌17 项研究
- 转移性癌症16 项研究
- 癌症（所有类型）14 项研究
- 急性髓系白血病14 项研究
- 头颈鳞状细胞癌13 项研究
- 膀胱癌11 项研究
- 胰腺癌11 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。